Avalo Therapeutics (AVTX) Proxy filing summary

Executive summary

• Annual Meeting scheduled for June 2, 2026, at 8:30 a.m. ET, to be held virtually.

• Shareholders are invited to vote on key proposals, including director elections, an employee stock purchase plan amendment, and auditor ratification.

Voting matters and shareholder proposals

• Election of seven directors to serve until the 2027 Annual Meeting.

• Approval of the Second Amended and Restated 2016 Employee Stock Purchase Plan.

• Ratification of Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026.

• Provision for other business to be conducted as properly brought before the meeting.

Board of directors and corporate governance

• Seven nominees for director positions are listed, including Michael Heffernan, Garry Neil, M.D., Kevin Lind, Rita Jain, M.D., Aaron Kantoff, Gilla Kaplan, Ph.D., and Samantha Truex.